Niche CDMO adds spray drying for highly potent drugs

28 Mar 2018

The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.

IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few CDMO to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.

Niche CDMO adds spray drying for highly potent drugs

The Spanish CDMO, which specialises in niche and highly potent products, will be one of only three companies in the world offering this type of contract development and manufacturing spray drying service with the installation of GEA Niro Mobile Minor equipment in a new dedicated area in its 4,000 sq. ft EU GMP plant.

The new equipment, which involves a significant investment for the company, will be installed and qualified in mid-2018 and will give Idifarma spray drying capacity for niche commercial products and clinical batches.

Luis Oquiñena, general manager and co-founder of Idifarma said: “We are excited to announce this new service and very proud to be at the forefront of spray drying technology. By making this investment, we will be able to provide contract manufacturing services for intermediate products, and for oral solid drugs we can continue until the finished dosage forms.

“This investment is driven by significant client demand, with the market looking for spray drying solutions as a suitable technology to improve the bioavailability of poorly soluble drugs. Idifarma now has all the ingredients to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”

This announcement follows recent investment in both serialisation and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.

Oquiñena added: “Our investment in new technologies reflects our continued success within the CDMO market and our intent to further grow our business with specialised capabilities. As well as new technologies we are also investing in qualified and experienced staff to deliver our services and now have 120 employees on site. As customer demand for our niche CDMO services continues to grow we fully expect both investments and staff numbers to increase steadily in the coming year.”

Read More

Related tags

Market News

Related news

FDA success for MedPharm Centre of Excellence

FDA success for MedPharm Centre of Excellence

14 Feb 2020

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

Read more 
Stevanato Group partners with Pfeiffer Vacuum to deliver effective biopharma industry testing

Stevanato Group partners with Pfeiffer Vacuum to deliver effective biopharma industry testing

12 Feb 2020

Partnership will provide biopharma companies with advanced container closure integrity analysis and testing protocols.

Read more 
Catalent to manufacture first-in-class mAb targeting solid tumours

Catalent to manufacture first-in-class mAb targeting solid tumours

11 Feb 2020

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more 
BD completes clinical trial for its wearable injector

BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

Read more 
Innovation awarded at Pharmapack

Innovation awarded at Pharmapack

10 Feb 2020

Innovations across primary and secondary packaging, drug delivery devices, and machinery acknowledged in Exhibitor Innovations, with Health Product Awards for patient-centricity and eco-design.

Read more 
2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
Recipharm acquisition to make it a top 5 global CDMO?

Recipharm acquisition to make it a top 5 global CDMO?

6 Feb 2020

CEO says the acquisition of Consort Medical will help to create a leading advanced delivery systems company.

Read more 
New Velesco Pharma clinical manufacturing facility begins operations

New Velesco Pharma clinical manufacturing facility begins operations

5 Feb 2020

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

Read more 
Colorcon starts No-Tox ink manufacturing at new UK facility

Colorcon starts No-Tox ink manufacturing at new UK facility

4 Feb 2020

The additional capacity will provide customers with shorter lead times and reduced transportation costs.

Read more 
Hovione announces key patent grants for its large dose DPI

Hovione announces key patent grants for its large dose DPI

4 Feb 2020

TwinMax enabes delivery of doses up to 100 mg formulated as drug alone or engineered particles.

Read more